Following on from the "Ka-ching Affair" comes this snippet in Friday's NYT:
The Centocor unit of Johnson & Johnson, the drug and consumer products maker, received a subpoena in connection with an investigation into pricing of its drug Remicade, a treatment for rheumatoid arthritis and other inflammatory diseases.
Johnson & Johnson, in a regulatory filing, said Centocor received a subpoena on Nov. 27, 2006, in connection with an investigation being conducted by the Office of the United States Attorney for the Central District of California.
According to the filing, the investigation was related to the average selling price calculations for Remicade under the company’s contract purchase program.
Source: New York Times
Insider's view: Oh dear. If it isn't one thing it's another.
And with all these bright drug reps being laid off by Big Pharma at the moment it looks like more might be thinking "dont get mad - get even" and start blowing the whistle on dubious practices.
After all "there's gold in them thair pills"!
1 comment:
What do you think this means for Centocor? There are a few drugs to compete with Remicade coming out in 2007. They don't require infusion centers so I don't think prices could be manipulated like with Remicade...but I may be wrong...
This really sucks, by the way, as a person getting Remicade for Crohn's Disease.
Post a Comment